The Drug Utilization Review (DUR) website is temporarily inaccessible. Meeting notices will be posted on this page until the DUR website is operational again.
House File 653 established a requirement for the Pharmaceutical and Therapeutics (P&T) Committee and the Drug Utilization Review (DUR) Commission to request and consider information from individuals who possess scientific or medical training with respect to drugs and biological products for rare diseases and drugs and biological products that are genetically targeted when making recommendations or determinations regarding beneficiary access.